Document is current
Any future updates will be listed below
-
Authors
Backeljauw, Philippe F.
Andrews, Mary
Bang, Peter
Dalle Molle, Leo
Deal, Cheri L.
Harvey, Jamie
Langham, Shirley
Petriczko, Elżbieta
Polak, Michel
Storr, Helen L.
Dattani, Mehul T. https://orcid.org/0000-0002-0365-5809
-
Funding
Funding for this research was provided by:
Ipsen Biopharmaceuticals
- License Information
-
More Information
Article History
Received: 24 October 2022
Accepted: 24 September 2023
First Online: 7 October 2023
Declarations
:
: Not applicable.
: Not applicable.
: Dr. Backeljauw has been a consultant for Novo Nordisk, Novartis/Sandoz, Tolmar Pharmaceuticals, Ascendis Pharma, BioMarin Pharmaceutical, Cavalry Bioventures, and Ipsen, and currently receives research support from Novo Nordisk and Novartis. Dr Bang has been a consultant for Sanofi-Aventis, Novo Nordisk, Merck Serono, Lilly, Ipsen, Sandoz, Versartis and Pfizer. Dr Deal has been a consultant for Pfizer, Merck/EMD-Serono, Eli Lilly, Ipsen, Lumos, Levo Therapeutics, GLWL Research Inc, Millendo, Versartis, Ferring, Bayer and Radius Pharmaceuticals. Dr Petriczko has been a consultant for Ipsen. Professor Storr has been a consultant for Sandoz, NovoNordisk, Ipsen and Springer. Professor Dattani has been a consultant for Ferring, Ipsen, Novo Nordisk, Pfizer and Sandoz. Mrs Andrews, Mr Dalle Molle, Mrs Harvey, Mrs Langham and Professor Polak declare no conflicts of interest.
